Cancure
  • Home
  • About
    • Vision
    • Board & Management
    • Scientific Advisors
  • Cancer
    • Current Treatments
    • Market
  • Therapies
    • Genvax – lead candidate CNC118
    • Galectin – lead candidate CNC225
    • Mitocans – lead candidate CNC332
    • Combination Therapy
    • Genvax vs. CAR-T
    • Development Program
    • References
  • Investors
    • Investors Snapshot
    • News
    • Public Documents
  • Contact
  • Glossary of Terms
  • Search
  • Menu Menu
Cancer Therapies

CANCER

Cancer is a deadly disease caused by uncontrolled cell growth. It is the world’s leading cause of death, followed by heart disease and stroke. According to Cancer Research UK, almost half of all people will be diagnosed with cancer during their lifetimes, and half of those will die from the disease. The 2012 World Health Organisation Cancer Report predicted “an imminent human disaster”, with the approximately 15 million new cases of cancer occurring worldwide annually expected to almost double within the next 20 years.

Current cancer drug therapy is largely limited to delaying the disease’s lethality. The cancer drug market has been, and for the foreseeable future will continue to be, dominated by conventional chemotherapy; however,  targeted therapy and immunotherapy are rapidly gaining traction.

Some industry analysts are calling next-generation immunotherapy the “beginning of the end” for cancer, reflecting the quantum leap in patient response rates being demonstrated for immuno-oncology therapies in late stage clinical development. Cancure’s pipeline is at the forefront of targeted therapy and immunotherapy for cancer.

  • Current Treatments
  • Market

NEWS

  • NousCom receives $49M to trial off-the-shelf cancer vaccine
  • AstraZeneca bolts Incyte’s IDO1 immunomodulator to its lung cancer plans
  • Incyte pays MacroGenics $150M for PD-1 inhibitor
  • Gilead buys CAR-T developer Kite Pharma for $12B

Contact

Mr Craig Miles
craig@cancure.com
+61 (0) 408 778 797
PO Box 1177, Broadbeach,
Queensland, Australia 4218

Copyright © 2021 All rights reserved.
  • Twitter
  • Dribbble
Scroll to top